A single intravenous ketamine infusion for depression typically costs between $400 and $800, depending on geographic location, clinic, and whether additional services such as psychological support are included. A standard initial treatment course of 6 infusions over 2 to 3 weeks therefore ranges from approximately $2,400 to $4,800. Ongoing maintenance infusions add recurring costs of $400 to $800 per session, typically every 2 to 6 weeks. These costs are predominantly out-of-pocket, as most insurance plans do not cover IV ketamine for psychiatric indications.
What Influences the Cost?
Several factors affect ketamine therapy pricing. Geographic location plays a significant role -- clinics in major metropolitan areas and coastal cities tend to charge at the higher end of the range, while clinics in smaller markets may offer lower prices. The clinical setting matters as well: hospital-based infusion centers may charge more than standalone ketamine clinics due to facility fees.
The scope of services included in the per-infusion fee varies considerably between providers. Some clinics include only the infusion itself and basic vital sign monitoring. Others bundle pre-treatment psychiatric evaluation, ongoing outcome measurement with validated depression scales, integration therapy sessions, and post-infusion support into a comprehensive package price. Patients should ask exactly what is included before committing to a treatment program.
Additional costs may include the initial psychiatric evaluation (typically $200 to $500), medical clearance testing if required, and any lab work such as liver function tests for patients receiving long-term treatment.
Comparing Treatment Options
While ketamine therapy represents a significant financial investment, the cost should be considered in context. For patients with treatment-resistant depression who have already tried multiple medications without success, the economic burden of ongoing disability, lost productivity, hospitalizations, and continued medication trials can far exceed the cost of ketamine treatment. A cost-effectiveness analysis published in peer-reviewed literature suggests that ketamine infusions may be cost-effective relative to continued treatment-as-usual in treatment-resistant populations.
FDA-approved intranasal esketamine (Spravato) is more likely to be covered by insurance but requires twice-weekly administration for the first month, in-office monitoring for at least 2 hours per session, and enrollment in a restricted distribution program, which carries its own logistical burdens.
For a complete overview of ketamine therapy including practical considerations, see the Complete Guide to Low-Dose Ketamine Therapy.
References
- PubMed: Cost-Effectiveness of Ketamine in Treatment-Resistant Depression — Economic analysis of ketamine therapy relative to standard-of-care treatments
- NIMH: Depression Treatment Research — National Institute of Mental Health information on depression treatment approaches
- Mayo Clinic: Treatment-Resistant Depression — Overview of treatment options and practical considerations
Share